Literature DB >> 16956442

Fever with rash following zolendronic acid administration.

E C Rizos, H J Milionis, M S Elisaf.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16956442

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


× No keyword cloud information.
  5 in total

1.  Diffuse adverse cutaneous reactions induced by zoledronic acid administration: a case report : Eruptions cutanées diffuses induites par l'administration de l'acide zolédronique.

Authors:  Kawtar Nassar; Saadia Janani
Journal:  Osteoporos Int       Date:  2021-06-03       Impact factor: 4.507

2.  Cutaneous side effects of antiosteoporosis treatments.

Authors:  Philippe Musette; Jean-Marc Kaufman; René Rizzoli; Patrice Cacoub; Maria Louisa Brandi; Jean-Yves Reginster
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-02       Impact factor: 5.346

3.  Nitric oxide-mediated cytotoxic effect induced by zoledronic acid treatment on human gingival fibroblasts.

Authors:  Marianna De Colli; Susi Zara; Viviana di Giacomo; Antonia Patruno; Guya Diletta Marconi; Marialucia Gallorini; Vincenzo Luca Zizzari; Giulia Tetè; Amelia Cataldi
Journal:  Clin Oral Investig       Date:  2014-10-30       Impact factor: 3.573

4.  Zoledronic acid at subtoxic dose extends osteoblastic stage span of primary human osteoblasts.

Authors:  Susi Zara; Marianna De Colli; Viviana di Giacomo; Vincenzo Luca Zizzari; Chiara Di Nisio; Umberto Di Tore; Vincenzo Salini; Marialucia Gallorini; Stefano Tetè; Amelia Cataldi
Journal:  Clin Oral Investig       Date:  2014-07-24       Impact factor: 3.573

Review 5.  Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity.

Authors:  P Musette; M L Brandi; P Cacoub; J M Kaufman; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2009-11-17       Impact factor: 5.071

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.